Ding · Science advances 2025 · Preclinical animal and in vitro mechanistic study with human tissue validation · n=?

Hepatic NMNAT1 is required to defend against alcohol-associated fatty liver disease.

Cited 7 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

Animal models, cellular mechanisms, and observational human tissue analysis

PubMed 40577472 · doi:10.1126/sciadv.adt6195 · record verified 2026-08-29

What was done

The authors investigated the function of nicotinamide mononucleotide adenylyltransferase 1 (NMNAT1) in alcohol-associated liver disease (ALD). They analyzed NMNAT1 expression in liver tissue from patients with alcohol-associated hepatitis and in ALD mouse models and primary hepatocytes. Using liver-specific NMNAT1 knockout mice, metabolomics, transcriptomics, and genetic or nutritional interventions (such as CSAD overexpression, taurine supplementation, and NMNAT1 replenishment), they explored the upstream regulatory mechanism (FBXW7-IRF1 axis) and downstream metabolic pathways.

What was found

NMNAT1 expression and activity were decreased in livers of patients with alcohol-associated hepatitis and in ALD mice. Alcohol exposure promoted FBXW7-regulated ubiquitination and degradation of IRF1, reducing NMNAT1 transcription. Hepatic NMNAT1 knockout exacerbated alcohol-induced NAD+ depletion, steatosis, and liver injury in mice, and abolished the protective effect of NMN. Mechanistically, cysteine sulfinic acid decarboxylase (CSAD)-regulated taurine pathways were impaired; both CSAD overexpression and taurine supplementation mitigated NMNAT1 knockout-induced ALD aggravation, while replenishing hepatic NMNAT1 reversed hepatic lipid accumulation. No numerical effect sizes or p-values were reported in the abstract.

Why it matters

This work identifies hepatic NMNAT1 and its downstream regulation of taurine metabolism as a central protective axis against alcohol-induced steatosis and liver damage. It suggests targeting nuclear NAD+ synthesis or taurine pathways may offer therapeutic utility in ALD.

Limits

The abstract provides no sample sizes for human tissue donors or animal cohorts, and reports no numerical data, variance, or statistical thresholds. Findings are predominantly mechanistic and derived from rodent and in vitro models, which may not fully reflect human ALD pathology.

Cited by